GLP-1 Obesity Drugs Fuel Plunge in Bariatric Surgery Rates, Creating Long-Term Uncertainty for Medtech
The rapid adoption of GLP-1 receptor agonist medications for obesity is reshaping adjacent healthcare sectors, most notably metabolic bariatric surgery and the medical technology (medtech) companies that support it.
A landmark study led by Harvard T.H. Chan School of Public Health researchers and published in JAMA Network Open analyzed health insurance data from over 17 million commercially insured U.S. patients. The study revealed that between 2022 and 2023, as prescriptions for GLP-1 medications for obesity patients more than doubled (increasing by 132.6% for patients without diabetes), the rate of metabolic bariatric surgery plummeted by 25.6%.
This trend represents a severe, structural shift in obesity care away from traditional, invasive anatomical surgeries (such as gastric bypass and sleeve gastrectomy) and toward medical pharmacotherapy.
Long-Term Medtech Implications
This shift has created substantial uncertainty for hospital systems and medical device manufacturers that derive significant revenue from bariatric procedures. Affected companies include:
- Intuitive Surgical (NASDAQ: ISRG): The developer of the da Vinci Surgical System, which is heavily utilized in robotic bariatric operations. Intuitive Surgical currently holds a market capitalization of $150.39 billion with a TTM revenue of $10.58 billion (+23.0% YoY) and is debt-free. Although the company continues to see strong overall procedure growth (18% growth in 2025 to 3.2 million procedures), the long-term impact of a sustained decline in bariatric surgery remains a key area of strategic focus.
- Other Medtech Giants: Companies like Johnson & Johnson (Ethicon) and Medtronic, which manufacture staplers, sutures, and laparoscopic equipment used in weight-loss surgeries, face similar headwind exposure.
Despite surgical declines, some medical experts note that bariatric surgery and GLP-1 medications may eventually become complementary. Some patients who undergo surgery require GLP-1s for weight maintenance, while others utilize GLP-1s to reduce surgical risks pre-operatively. Nonetheless, the immediate effect is a significant headwind for bariatric surgical volumes.
Quotes
From the study's lead author, Thomas Tsai (Harvard T.H. Chan School of Public Health):
“Right now there’s just a high degree of uncertainty for what this all means in terms of bariatric surgery volume in the long-term. But for patients, with all the different treatment options that now exist, this truly is a golden age.”
From the JAMA Network Open study:
"In the study, researchers analyzed health insurance data from over 17 million people in the U.S. They found that between 2022 and 2023, prescriptions of GLP-1 medications for obesity patients more than doubled, while the rate of bariatric surgery decreased by 25.6%."